Transdermal hormone replacement therapy
US5422119A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Jan 3, 1994 |
| Grant date | Jun 6, 1995 |
| Priority date | — |
| Expiry date | Jan 3, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/57
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method of treating a female in need of hormone replacement therapy comprising transdermally administering to said female a series of alternating phases of from about one to about four days of estrogen dominant activity and phases of from about one to about four days of progestin dominant activity, with the estrogen dominant activity phase consisting of administering a transdermal estrogen substance alone or administering a transdermal estrogen substance and a transdermal progestin substance and the progestin dominant activity phase consisting of administering a transdermal progestin substance and a transdermal estrogen substance, the amount of progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.